AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01374425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180 mg/m\^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
Study NCT01374425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 400 mg/m\^2 or dose deemed appropriate by Investigator via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
Study NCT01374425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m\^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
Study NCT01374425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 850 or 1000 mg/m\^2 may be offered in the event of unacceptable toxicity to oxaliplatin or irinotecan, to be given orally twice a day on Days 1 to 14 in 3-week cycles.
Study NCT02655887 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VENOVO™ Venous Stent
Description: VENOVO™ Venous stent placement
Study NCT03279926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAY
Description: Activity trackers + curriculum information
Study NCT03279926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAY Parents
Description: Enhanced parental engagement
Study NCT03279926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAY Teachers
Description: Enhanced teacher engagement with active living initiates for the teachers
Study NCT01192880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive bitopertin matching placebo once daily for 56 weeks.
Study NCT01192880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bitopertin
Description: Participants will receive 10 mg or 20 mg of bitopertin.
Study NCT01192880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipsychotics
Description: Participants will continue to receive their stable antipsychotic regiment throughout the study. Study protocol does not specify any particular antipsychotic drug and regimen.
Study NCT01192880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antipsychotics
Description: Participants will continue to receive their stable antipsychotic regiment throughout the study. Study protocol does not specify any particular antipsychotic drug and regimen.
Study NCT02834819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Nebulized Hypertonic Saline
Study NCT01146145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: intravenous morphine titration combined to ketamine
Study NCT01146145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: intravenous morphine titration combined to ketamine
Study NCT04138095 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Virtual Reality
Description: Participants will have access to an Oculus Quest Virtual Reality Headset every second day as an alternative to opioids for pain management and benzodiazepines for anxiety management
Study NCT00726102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cereal
Description: Daily provision of cereal to infants from 6-18 mos
Study NCT00726102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fortified rice cereal
Description: Daily provision of fortified cereal to infants 6-18 months of age
Study NCT00064350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sorafenib
Description: Step 1 (induction): Sorafenib was giventwice daily for two cycles to all patients. Patients with progression (PD) discontinued treatment. Those who responded after two cycles continued treatment up to 1 year or until PD. With response after 1 year, patients were given the option to continue treatment until PD. Patients who were stable after the end of induction were then randomized onto Step 2 to either continue sorafenib or receive placebo.~Step 2 (randomization): Patients with stable disease after induction will be randomized in a double-blinded manner to placebo or sorafenib. If a patient has progressed, the arm will be unblinded. Patients on placebo with PD can then crossover to receive sorafenib; patients with PD on the sorafenib arm will be removed from the study.~Step 3 (crossover): If patients on placebo progressed within 1 year from randomization, they crossed over to the treatment arm and receive sorafenib for up to 1 year or until PD, unacceptable toxicity, or death.
Study NCT00064350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Step 1 (induction): Sorafenib was giventwice daily for two cycles to all patients. Patients with progression (PD) discontinued treatment. Those who responded after two cycles continued treatment up to 1 year or until PD. With response after 1 year, patients were given the option to continue treatment until PD. Patients who were stable after the end of induction were then randomized onto Step 2 to either continue sorafenib or receive placebo.~Step 2 (randomization): Patients with stable disease after induction will be randomized in a double-blinded manner to placebo or sorafenib. If a patient has progressed, the arm will be unblinded. Patients on placebo with PD can then crossover to receive sorafenib; patients with PD on the sorafenib arm will be removed from the study.~Step 3 (crossover): If patients on placebo progressed within 1 year from randomization, they crossed over to the treatment arm and receive sorafenib for up to 1 year or until PD, unacceptable toxicity, or death.
Study NCT00064350 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sorafenib
Description: Step 1 (induction): Sorafenib was giventwice daily for two cycles to all patients. Patients with progression (PD) discontinued treatment. Those who responded after two cycles continued treatment up to 1 year or until PD. With response after 1 year, patients were given the option to continue treatment until PD. Patients who were stable after the end of induction were then randomized onto Step 2 to either continue sorafenib or receive placebo.~Step 2 (randomization): Patients with stable disease after induction will be randomized in a double-blinded manner to placebo or sorafenib. If a patient has progressed, the arm will be unblinded. Patients on placebo with PD can then crossover to receive sorafenib; patients with PD on the sorafenib arm will be removed from the study.~Step 3 (crossover): If patients on placebo progressed within 1 year from randomization, they crossed over to the treatment arm and receive sorafenib for up to 1 year or until PD, unacceptable toxicity, or death.
Study NCT00064350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to the placebo arm in step 2 continued receiving placebo until disease progression or one year from randomization. Placebo was given orally twice a day (BID).
Study NCT02709473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol will be used in either two arms. The injection sequence will be changed. In propofol arm of the study, general anesthesia will be started with 2 mg/kg propofol administered within 15 seconds. And, then remifentanil will be given. In remifentanil arm of the study, 2 mg/kg propofol will be applied within 15 seconds following remifentanil injection.
Study NCT02709473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil will be used in either two arms. The injection sequence will be changed. In remifentanil arm, general anesthesia will be started with 2 μg/kg remifentanil administered within 30 seconds. And then propofol will be given. In propofol arm of the study the same dose will be applied within 30 seconds following propofol administration.
Study NCT02709473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Rocuronium will be used for either two study arms. Rocuronium will be given in a 0.8 mg/kg dosage in the first study subject. And then, if the intubation condition is acceptable, the dose of the rocuronium will be decreased by 0.1 mg/kg for the next patient. Otherwise, if the intubation condition is not acceptable, the rocuronium dosage will be increased by 0.1 mg/kg for the next patient. This will be continue for ten crossover points (the point that turn from unsuccessful intubation to successful intubation).
Study NCT01963208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganaxolone
Description: 200 mg and 225 mg capsules; target dose 1800 mg/day dosed 900mg 2x/day
Study NCT01963208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04300062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rebiopsy
Description: Biopsy will be carry out with flexible bronchoscopy as usual practice under local anesthesia: under endobronchial ultrasound, punction under CT scan or ultrasonography, percutaneous pleural puncturing.
Study NCT01262755 — intervention group
Intervention type: BEHAVIORAL
Intervention: Structured Interview
Description: Subjects underwent a structured interview using a laptop computer and answered over 200 standardized questions. All patient had their height, weight, and waist circumference measured.
Study NCT04224428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine Pill
Description: fexofenadine tablets 60 mg once daily will be taken for six months
Study NCT04224428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: lactose oral tablet
Study NCT00199134 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole
Description: Size of the tumor is followed
Study NCT02623049 — intervention group
Intervention type: OTHER
Intervention: New oral anticoagulant pharmacodynamic analysis (blood level assesment)
Study NCT03064438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACCU-D1
Description: ACCU-D1
Study NCT03064438 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Placebo Comparator
Study NCT02709486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: 2.5 mg
Study NCT02709486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: 5 mg
Study NCT02709486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03495401 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortified synbiotic milk
Description: 100 ml fortified (7,47 mg ferrous sulphate and 4,33 mg zinc acetate) synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
Study NCT03338348 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vosaroxin
Description: Cycle 1-8: Dose Level 0: 70mg/m², Dose Level -1: 50mg/m², Dose Level -2: 40mg/m², IV over ten minutes, d 1+4 .
Study NCT03338348 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azacitidine
Description: Cycle 1-8 Azacitidine: 75 mg/m²/d subcutaneously, d 1-7;~Maintenance with single agent azacitidine at 75 mg/m²/d on days 1-7 until relapse or progression.
Study NCT02790307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Geko
Description: transcutaneous tibial nerve stimulation (stick on patch)
Study NCT01900496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Day 1 every three weeks (weeks 0, 3, 6, 9, ... 27): 1.8 mg/kg IV. Ten doses maximum.
Study NCT01900496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Day 1 of weeks 12, 13, 14, 15, 18, 21, 24, and 27: 375 mg/m\^2 IV. Additional doses are given at three and six months post week 27.
Study NCT03604341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol 5mg Cap
Description: Subjects randomized to Dronabinol 5mg Cap and ibuprofen 800mg for pain
Study NCT03604341 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo and ibuprofen 800mg for pain
Study NCT00901147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat and bortezomib
Description: oral panobinostat 30 mg 3 times per week AND intravenous bortezomib 1.3mg/m2 on days 1,4,8,11 per cycle
Study NCT02810652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care participants will not meet with a geriatric clinician perioperatively, though they may receive a geriatric consult at their request or at the discretion of their treating cancer team.
Study NCT02810652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perioperative Geriatrics Intervention
Description: Patients randomized to the perioperative geriatrics intervention will undergo evaluation with a board-certified Massachusetts General Hospital (MGH) geriatric clinician, both pre- and post-operatively. The geriatric clinician visits will focus on the following issues: comorbidity, polypharmacy, nutrition, physical and mental function, and social support.
Study NCT01234857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus + dalotuzumab
Description: Ridaforolimus 20 mg once daily (QD) five days a week, with the possibility of escalation to 30 mg once daily (QD) after the first cycle and dalotuzumab intravenous infusion 10 mg/kg once weekly (QW). Treatment will continue until disease progression.
Study NCT03495401 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: non-fortified synbiotic milk
Description: 100 ml non-fortified synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
Study NCT01119638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Patients in the escitalopram group will receive 5 mgs/d for the first week and than 10 mgs/d till completion.
Study NCT01234857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane
Description: Exemestane 25 mg daily (QD). Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval.
Study NCT01234857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: Ridaforolimus 40 mg QD five days a week. Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval. Note: the Sponsor-recommended dose of ridaforolimus when administered as a single agent is 40 mg/day, but when given in combination with dalotuzumab, it is given at 30 mg/day.
Study NCT01234857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: Dalotuzumab intravenous infusion 10 mg/kg QW. Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval.
Study NCT02860845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boric acid and probiotics
Description: Vaginal capsules administered once a day during 7 days.
Study NCT02860845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic (Clindamycin)
Description: Vaginal capsules containing a reference antibiotic (when bacterial vaginosis is suspected) administered once a day during 3 days.
Study NCT02860845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antifungal (Clotrimazole)
Description: Vaginal capsules containing a reference anti-fungal (when candidiasis is suspected) administered once a day during 6 days.
Study NCT03489616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Description: rhGM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils. rhGM-CSF can promote the maturation of dendritic cells and macrophage, increase their antigen presentation ability.
Study NCT01815801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lungs were mechanically ventilated during subclavian vein catheterization
Description: Ventilated group
Study NCT03489616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer.
Study NCT02581878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1862864
Description: Radiopharmaceutical, injection: Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. In this dose-escalation part of the study, the radioactivity dose will start at 1.5 MBq and increase in steps of 1.5 MBq, with a antibody-chelator conjugate dose of 2 or 10 mg.
Study NCT03489616 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Local Radiotherapy
Description: Radiotherapy promotes the release of tumor antigen
Study NCT03489616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single agent
Description: Other chemotherapy drugs,such as Docetaxel, gemcitabine
Study NCT03064958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbs and spices
Description: Mix of commonly used herbs and spices
Study NCT03064958 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High fat meal
Description: Meal containing 1000kcal and 45g fat
Study NCT03064958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat meal
Description: Meal containing 1000kcal and 45g fat
Study NCT02165618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication review, based on but not limited to the RASP list
Description: Systematic approach:~1. Medication reconciliation~2. Applying the RASP list~3. Expert review (not based on the RASP list)~4. Multidisciplinary discussion
Study NCT01119638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Patients in the risperidone group will receive 0.5 mgs/d for the first week and than 1.0 mg/d till completion.
Study NCT02373904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photodynamic Bone Stabilization System
Description: Treatment of impending and actual pathological fractures of the humerus
Study NCT00776789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin to skin contact
Description: Infants randomized to SSC group were placed prone over the mother's chest immediately after birth. Skin-to-skin contact was continued for the next two hours. breastfeeding at the time of discharge.
Study NCT00776789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: The infants who were allocated to the conventional care (control group) were kept by the mother's side and did not receive early SSC.
Study NCT00736983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 24 weeks: 160 mg, 80 mg, and than 40mg every 2 weeks
Study NCT00736983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ciprofloxacin
Description: 12 weeks; daily 2 x 500mg
Study NCT02989181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continues Positive Airway Pressure (CPAP)
Description: Mask with positive airway pressure during exhalation which maintains the airway open
Study NCT00109837 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: As needed per physician discretion
Study NCT00109837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide Consolidation: 650 mg/m2; IV; days 1, 15, 29 Post-consolidation course 3: 650 mg/m2; IV; day 1
Study NCT01302925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 Gel
Description: PEP005 Gel 0.05% for 2 consecutive days
Study NCT01302925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 Gel
Description: PEP005 Gel 0.015% for 3 consecutive days
Study NCT02205320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DRL_PG
Study NCT04223700 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging & fluoroscopic confirmation
Description: The researchers use ultrasound to scan the left and right sides of the paravertebral sagittal imaging to identify trapezius, semispinalis, erector spinae muscle, transverse process and rhomboid muscle. The radiopaque marker is attached respectively to the skin of the inferior margin of the rhomboid muscle on the left and right thoracic spinal spines. Then, as the first step for the scheduled nerve block to the patient, thoracic vertebra level verification using C-arm is performed. At this time, left and right level of the transverse process of thoracic spine marked with the radiopaque marker are confirmed and recorded.
Study NCT05414305 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Heparin & Alkalinized Lidocaine Bladder Instillation
Description: Bladder instillation instilled via catheter and to dwell for minimum of 30 minutes prior to spontaneous void
Study NCT03420326 — intervention group
Intervention type: BEHAVIORAL
Intervention: Frailty status assessment
Description: The Edmonton frail scale and Frailty criteria by Dr. Fried would be used to assess participants frailty status
Study NCT00109837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Induction 2: 3 g/m2; IV over 3 hrs; days 1-5 Consolidation: 75 mg/m2/d; IV push; days 2-5 and 16-19 Post-consolidation course 3: 75 mg/m2/d; IV push; days 3-6 and 10-13
Study NCT00109837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin
Description: Induction: 60 mg/m2/d; IV; days 1, 2, and 3